UBS maintains China Vanke-H Sell rating as FY2025 net loss exceeds warning and cash flow remains under pressure

Overview

UBS released a research report on China Vanke-H with a broadly negative view. Vanke's FY2025 loss was larger than the earlier profit warning, with credit impairment, asset impairment, declining sales in the development business, and margin pressure all weighing on performance. Although free cash flow improved in the second half versus the first half, it still has not turned positive, net debt continues to rise, and the deleveraging process may last for several years.

Core views

UBS keeps its Sell rating on Vanke, believing the company still faces years of deleveraging pressure before reaching free-cash-flow break-even. The report also notes that although the company has received refinancing, new financing, and shareholder-loan support from Shenzhen Metro, and has repaid part of its public debt, extension requests for some medium-term notes and corporate bonds show that refinancing risk has not been fundamentally resolved.

Analysis framework

The report evaluates Vanke along the lines of a quick earnings review, cash flow and balance-sheet pressure, financing support, valuation multiples, and risk scenarios. The earnings analysis compares the actual results for 2H25 with forecast, 1H25, and 2H24 data; valuation uses a P/BV multiple and UBS's 12-month forecast stock return framework to derive the rating.

Methodology notes

• Valuation methodsP/BV valuation method

  price-to-book multiple

  UBS says Vanke's target price is based on a P/BV multiple, reflecting the importance of balance-sheet strength and net asset quality in valuing a real estate developer.

• Rating frameworkForecast Stock Return

  forecast stock return

  UBS defines forecast stock return as the sum of expected share price upside over the next 12 months plus dividend yield, compared with the market return assumption; in this report, Vanke's forecast stock return is -10.7% and forecast excess return is -21.5%.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Vanke-H（2202.HK）

  Core covered name

  Strengths

  A nationwide developer, ranked China's second-largest developer by contracted sales in 2023, with operations across more than 70 cities and businesses spanning logistics real estate, commercial real estate, and property management.

  Weaknesses

  Large FY2025 loss, negative free cash flow, continued increase in net debt, and weaker sales and margins in the development business.

  Comparison

  Compared with the market return assumption of 10.9%, the report's forecast stock return is -10.7%, and forecast excess return is -21.5%.

  Risks

  Refinancing risk, asset impairment, weaker sales, margin pressure, and a prolonged deleveraging cycle.

• China Vanke A shares（000002.SZ）

  A-share security of the same company

  Strengths

  Shares the same fundamentals and asset base as the H-share.

  Weaknesses

  The report also assigns a Sell rating to the A-share, with a disclosed price of RMB 3.99.

  Comparison

  The A-share's historical target price and share price have also trended downward overall since 2022.

  Risks

  Similar to the H-share, affected by the real estate industry, financing conditions, and company cash flow pressure.

Key data

• FY2025 net lossRMB 88.6 billionAbove the earlier RMB 82.0 billion loss warning.
• Credit impairment and asset impairmentRMB 34.2 billion / RMB 21.9 billionThe report views this as one of the key reasons the loss exceeded the warning.
• 2H25 free cash flow-RMB 3.4 billionImproved quarter on quarter from -RMB 8.42 billion in 1H25, but still negative.
• Net debt including shareholder loansRMB 294.0 billionContinued to deteriorate from RMB 291.0 billion in 1H25.
• 2025 financing supportRMB 28.0 billion in refinancing and new financing; RMB 33.5 billion in shareholder loansThe shareholder loans came from Shenzhen Metro.
• Public debt repaidRMB 33.2 billionHowever, extension approval for part of the original November-maturity debt was only obtained from holders in January 2026.
• Target priceHK$2.6012-month target price.
• 12-month ratingSellUBS maintains its Sell rating.
• Market capHK$33.8 billion / US$4.32 billionMarket indicators disclosed in the report.

Impact & implications

The implication for Vanke-H shares is negative: profit, cash flow, and leverage pressure remain valuation constraints. External financing and shareholder support can ease short-term liquidity, but they are not enough to eliminate refinancing risk. If sales, asset disposals, or policy support come in below expectations, the company's share price and credit outlook may remain under pressure.

Risks

• Refinancing risk has not been fully resolved.
• Free cash flow remains negative, which may prolong the deleveraging cycle.
• Declining sales and margins in the development business.
• Credit and asset impairment continue to weigh on earnings.
• Oversupply in some cities may pressure margins.
• Tighter mortgage lending may affect the cash collection cycle.

What to watch

• Any additional funding support from Shenzhen Metro or other shareholders, or from the government.
• Progress on medium-term note and corporate bond extensions, refinancing, and the pace of public debt repayment.
• Whether contracted sales beat expectations.
• Whether asset disposals can be completed at a premium.
• Further easing of real estate policy in high-tier cities.
• When free cash flow moves close to or reaches break-even.